Search

Search Constraints

You searched for: Author/Creator Rovira, Jordina

Search Results

1. Early progression in follicular lymphoma in the absence of histological transformation or high‐risk Follicular Lymphoma International Prognostic Index still has a favourable outcome. (19th October 2022)

2. Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era. (18th February 2020)

3. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. (August 2017)

4. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. (4th December 2018)

5. Revised International Prognostic Index and genetic alterations are associated with early failure to R‐CHOP in patients with diffuse large B‐cell lymphoma. (10th October 2021)

6. T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome. Issue 4 (3rd April 2017)

7. Validation of the NCCN‐IPI for diffuse large B‐cell lymphoma (DLBCL): the addition of β2‐microglobulin yields a more accurate GELTAMO‐IPI. (20th January 2017)